Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
| 4.925 | |
| 4.99 | |
| - | |
| 4.9999 | |
| 4.8 | |
| 3.03-5.98 | |
| 168 M | |
| 34 341 K | |
| 0 | |
| -0.26 | |
| 1.547 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Milestone Pharmaceuticals Inc. – Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLO...
SEATTLE and VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and com...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
